- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 01.06. | LYTIX BIOPHARMA ASA: Lytix Biopharma Reports Phase II Data in Melanoma and Triple-Negative Breast Cancer for Ruxotemitide (LTX-315) in Combination with Pembrolizumab | 1 | Cision News | ||
| 21.05. | LYTIX BIOPHARMA ASA: Lytix Biopharma Q1 2026: Clinical Development Priorities On Track as Registrational Path Planning Advances | 2 | Cision News | ||
| LYTIX BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| 15.05. | LYTIX BIOPHARMA ASA: Lytix Biopharma: Invitation to the Q1 2026 Results Presentation | 1 | Cision News | ||
| 06.05. | LYTIX BIOPHARMA ASA: New Phase II Study Data from Lytix Biopharma's Partner Verrica Pharmaceuticals to be Presented at SID 2026 Highlight Potential Abscopal Effects of Ruxotemitide in Basal Cell Carcinoma | 19 | Cision News | ||
| 21.04. | Lytix Biopharma ASA to Showcase Promising Phase II Results for Ruxotemitide Combination Therapy at ASCO 2026 | 1 | Cision News | ||
| 21.04. | Lytix Biopharma ASA Reports Promising Final Phase II Results for Ruxotemitide (LTX-315) in Combination with Pembrolizumab in PD-1/PD-L1 Refractory Advanced Melanoma | 7 | Cision News | ||
| 16.04. | Lytix Biopharma ASA - Conversion to public limited liability company and name change registered | 1 | Cision News | ||
| 14.04. | Lytix Biopharma AS: Minutes from Annual General Meeting | 1 | Cision News | ||
| 09.04. | Lytix Biopharma AS: MANDATORY NOTIFICATION OF TRADE BY PRIMARY INSIDER - GRANT OF SHARE OPTIONS | 1 | Cision News | ||
| 07.04. | Lytix Biopharma Names Renée Christine Amundsen COO With Immediate Effect | 1 | RTTNews | ||
| 07.04. | LYTIX BIOPHARMA AS: Lytix Biopharma Appoints Renée Christine Amundsen as Chief Operating Officer to Support Next Phase of Growth | 1 | Cision News | ||
| 25.03. | Lytix Biopharma AS: Notice of Annual General Meeting on 14 April 2026 | 6 | Cision News | ||
| 24.03. | Lytix Biopharma AS: Annual Report for 2025 | 2 | Cision News | ||
| 18.03. | LYTIX BIOPHARMA AS: Lytix Biopharma to Present Final Phase II ATLAS-IT-05 Data at the AACR Annual Meeting 2026 | 4 | Cision News | ||
| 24.02. | Lytix Biopharma AS - New share capital registered | 3 | Cision News | ||
| 17.02. | LYTIX BIOPHARMA AS: Lytix Biopharma Publishes Comprehensive Review on the Transformative Potential of Oncolytic Peptides in Leading Cancer Journal (JITC) | 3 | Cision News | ||
| 12.02. | LYTIX BIOPHARMA AS: Lytix Biopharma: Q4 2025 Presentation and Publication of H2 2025 Interim Report | 1 | Cision News | ||
| 05.02. | LYTIX BIOPHARMA AS: Lytix Biopharma: Invitation to Q4 2025 Results Presentation and Publication of H2 2025 Report | 1 | Cision News | ||
| 12.01. | XFRA CAPITAL ADJUSTMENT INFORMATION - 12.01.2026 | 1.220 | Xetra Newsboard | Das Instrument PGH DE000A1MMEV4 THE PAYM.GR.HLDG KG NA ON EQUITY wird cum Kapitalmassnahme gehandelt am 12.01.2026 und ex Kapitalmassnahme am 13.01.2026 The instrument PGH DE000A1MMEV4 THE PAYM.GR.HLDG... ► Artikel lesen |
19 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| LINEAGE CELL THERAPEUTICS | 1,042 | -6,96 % | Regenerative Medizin im Aufbruch: NurExone Biologic, Regenxbio und Lineage Cell Therapeutics setzen auf unterschiedliche Zukunftstechnologien | ||
| DARWIN AG | 7,400 | +0,68 % | EQS-News: Darwin AG informiert über die Ergebnisse der ordentlichen Hauptversammlung 2026 | EQS-News: Darwin AG
/ Schlagwort(e): Hauptversammlung
Darwin AG informiert über die Ergebnisse der ordentlichen Hauptversammlung 2026
26.06.2026 / 17:00 CET/CEST
Für... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 132,66 | +0,08 % | Apogee Therapeutics: Hier dürfte zum US-Handelsstart heute die Post abgehen! | AbbVie steht laut einem Bericht kurz vor der Übernahme von Apogee Therapeutics für rund 10,9 Milliarden US-Dollar in bar. Der mögliche Aufschlag liegt bei etwa 60 Prozent. Weil die US-Börsen am Freitag... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 349,93 | +6,75 % | Praxis Precision Medicines, Inc. - 8-K, Current Report | ||
| TANGO THERAPEUTICS | 32,550 | +3,43 % | Tango Therapeutics, Inc.: Tango Therapeutics Appoints Robert Azelby to Board of Directors | BOSTON, June 22, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer... ► Artikel lesen | |
| QIAGEN | 34,570 | +0,14 % | DZ BANK stuft QIAGEN NV auf 'Kaufen' | FRANKFURT (dpa-AFX Analyser) - Die DZ Bank hat den fairen Wert für Qiagen von 38 auf 40 Euro angehoben und die Einstufung auf "Kaufen" belassen. Das Thema Künstliche Intelligenz (KI) sei für den Life-Science-Zuliefersektor... ► Artikel lesen | |
| VERA THERAPEUTICS | 43,130 | +1,58 % | Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgA Nephropathy | Prescription Drug User Fee Act (PDUFA) date of July 7, 2026 for Biologics License Application (BLA) for accelerated approval of atacicept in patients with IgA Nephropathy (IgAN)Revised ORIGIN 3 eGFR... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 109,43 | +1,21 % | Top Biotech Gainers: TECH Bought Out, MSLE On Watch, KYMR Hits New High, What's The Buzz At SLS? | OTTAWA (dpa-AFX) - Today's top gainers in the biotech space include Bio-Techne, following acquisition news; Satellos Bioscience, gearing up to present new DMD data next month; and Kymera, which... ► Artikel lesen | |
| ERASCA | 18,290 | +14,24 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| COGENT BIOSCIENCES | 38,740 | +1,68 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress | -- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an updated objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 35,340 | -0,37 % | Harmony Biosciences Stock Outlook as Wakix Growth Meets Pipeline | ||
| MINERALYS THERAPEUTICS | 26,880 | +0,75 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing | - Repurchase of lorundrostat royalty obligation in Tanabe license agreement for $200 million upfront and up to $100 million once certain commercial milestones are met - - $500 million committed... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 62,41 | +5,42 % | Kiniksa Pharmaceuticals Aktie markiert Rekordhoch bei 59,89 USD | ||
| ABSCI | 11,345 | +4,18 % | Morning Market Movers: Cuprina Holdings, CEA Industries, Absci, The Wendy's Company See Big Swings | MEMPHIS (dpa-AFX) - At 7:10 a.m. ET on Wednesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 14,310 | +2,14 % | Bernstein hebt Kursziel für Summit Therapeutics Aktie aufgrund von Studienaussichten an |
Das Unternehmen LYTIX BIOPHARMA ASA kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,024 (-2,93 %) liegt der Kurs bei 0,794 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LYTIX BIOPHARMA ASA finden Sie auf Wallstreet Online.